Originally published as JCO Early Release 10.1200/JCO.2005.01.4746 on August 29 2005
Journal of Clinical Oncology, Vol 23, No 29 (October 10), 2005: pp. 7278-7285
© 2005 American Society of Clinical Oncology.
Breast Cancer Prognosis Determined by Gene Expression Profiling: A Quantitative Reverse Transcriptase Polymerase Chain Reaction Study
E. Espinosa,
J.A. Fresno Vara,
A. Redondo,
J.J. Sánchez,
D. Hardisson,
P. Zamora,
F. Gómez Pastrana,
P. Cejas,
B. Martínez,
A. Suárez,
F. Calero,
M. González Barón
From the Service of Medical Oncology, Hospital La Paz; and Translational Oncology Unit and Department of Preventive Medicine, School of Medicine, Universidad Autónoma; and the Services of Pathology and Gynecology, Hospital La Paz, Madrid, Spain
Address reprint requests to E. Espinosa, MD, Servicio de Oncología Médica, Hospital La Paz, P° de la Castellana, 261—28046 Madrid, Spain; e-mail: eespinosa00{at}terra.es.
PURPOSE: We sought to reproduce with quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) the results obtained with a 70-gene expression profile that has been described previously in breast cancer.
PATIENTS AND METHODS: Frozen breast cancer samples from patients who were operated on were used to isolate tumor RNA. Ninety-six patients with stage I to II disease were included. Median age was 57 years (range, 27 to 80 years). Forty-eight patients had lymph node–negative and 48 lymph node–positive disease. qRT-PCR amplifications were performed and the results were correlated with clinical data.
RESULTS: After a minimum follow-up of 5 years, 25 patients had a relapse. The gene profile divided patients into two groups with poor and good prognosis. Significant differences with regard to grade of differentiation, size and hormone receptors were seen between the two groups. The gene profile was significantly associated with relapse-free survival and overall survival in the whole group of 96 patients. Multivariate analysis showed that only lymph node status and gene profile were significantly correlated to overall survival.
CONCLUSION: qRT-PCR reproduced the results obtained with microarrays for a prognostic gene profile in women with early-stage breast cancer.
Supported by Grant No. FIS 020568, a grant from Red de Centros de Epidemiología y Salud Pública (Universidad Autónoma of Madrid), Grant No. RTICC C03/10 from Instituto de Salud Carlos III, and unrestricted grants from Amgen, AstraZeneca, Bristol-Myers Squibb, Lilly, Novartis, Roche, Sanofi-Aventis, and Schering-Plough.
Presented at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 7-11, 2004.
E.E. and J.A.F.V. contributed equally to this study.
Terms in blue are defined in the glossary, found at the end of this issue and online at www.jco.org.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
This article has been cited by other articles:
|
|
|
|
 
C.-C. Huang and M. Bredel
Use of Gene Signatures to Improve Risk Estimation in Cancer
JAMA,
April 2, 2008;
299(13):
1605 - 1606.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. G. Yulug and B. Gur-Dedeoglu
Functional genomics in translational cancer research: focus on breast cancer
Brief Funct Genomic Proteomic,
March 7, 2008;
(2008)
eln009v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
J. Clin. Oncol.,
November 20, 2007;
25(33):
5287 - 5312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K Gruvberger-Saal, H. E Cunliffe, K. M Carr, and I. A Hedenfalk
Microarrays in breast cancer research and clinical practice - the future lies ahead
Endocr. Relat. Cancer,
December 1, 2006;
13(4):
1017 - 1031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Loi, C. Sotiriou, M. Buyse, E. Rutgers, L. V. Veer, M. Piccart, and F. Cardoso
Molecular Forecasting of Breast Cancer: Time to Move Forward With Clinical Testing
J. Clin. Oncol.,
February 1, 2006;
24(4):
721 - 722.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Brenton, A. A. Ahmed, and C. Caldas
In Reply:
J. Clin. Oncol.,
February 1, 2006;
24(4):
722 - 723.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Koscielny, S. Michiels, V. Boige, and C. Hill
Validation of Microarray Data by Quantitative Reverse-Transcriptase Polymerase Chain Reaction
J. Clin. Oncol.,
December 20, 2005;
23(36):
9439 - 9440.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Workman and P. G. Johnston
Genomic Profiling of Cancer: What Next?
J. Clin. Oncol.,
October 10, 2005;
23(29):
7253 - 7256.
[Full Text]
[PDF]
|
|
|
|
